Top

Published in:

01-07-2012 | Short Communication

Angiogenin levels are increased in lesional skin and sera in patients with erythrodermic cutaneous T cell lymphoma

Authors: Tomomitsu Miyagaki, Makoto Sugaya, Hiraku Suga, Kaname Akamata, Hanako Ohmatsu, Hideki Fujita, Yoshihide Asano, Yayoi Tada, Takafumi Kadono, Shinichi Sato

Published in: Archives of Dermatological Research | Issue 5/2012

Abstract

Angiogenin is a member of the ribonuclease superfamily that is associated with the angiogenic process. Angiogenesis is regarded as an important step to support primary and metastatic tumor growth. In cutaneous T cell lymphoma (CTCL), angiogenesis in lesional skin is increased, suggesting that interaction between tumor cells and their microvasculature are likely to occur during progression of CTCL. Patients with hematological malignancies show increased serum angiogenin levels, which are related with poor overall survival. To investigate possible roles of angiogenin in development of CTCL, we measured serum angiogenin levels in 36 patients with CTCL and 21 healthy controls by enzyme-linked immunosorbent assay. We also investigated angiogenin mRNA and protein expression in lesional skin of CTCL by quantitative RT-PCR and immunohistochemistry. Serum angiogenin levels in patients with CTCL were significantly higher than those in healthy controls. When classified with types of skin lesions, serum angiogenin levels were elevated only in erythrodermic CTCL patients. Angiogenin mRNA expression levels in lesional skin were significantly elevated in erythrodermic CTCL compared to normal skin. Immunohistochemical study revealed that angiogenin was expressed by keratinocytes, endothelial cells, and infiltrating lymphocytes in CTCL. Our results suggest that enhanced angiogenin expression may be related with a poor prognosis of erythrodermic CTCL. As angiogenin acts as an inhibitor of polymorphonuclear leukocyte degranulation, angiogenin may also be linked to impaired host defense in erythrodermic CTCL.

Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, Robson A, Calonje E, Stefanato CM, Wain EM, Wilkins B, Fields PA, Dean A, Webb K, Scarisbrick J, Morris S, Whittaker SJ (2010) Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28:4730–4739PubMedCrossRef

Alexandrakis MG, Passam FH, Pappa CA, Sfiridaki K, Tsirakis G, Damilakis J, Stathopoulos EN, Kyriakou DS (2005) Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes. Leuk Res 29:41–46PubMedCrossRef

Axelrod PI, Lorber B, Vonderheid EC (1992) Infections complicating mycosis fungoides and Sézary syndrome. JAMA 267:1354–1358PubMedCrossRef

Brunner B, Gunsilius E, Schumacher P, Zwierzina H, Gastl G, Stauder R (2002) Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Haematother Stem Cell Res 11:119–125CrossRef

Fett JW, Strydom DJ, Lobb RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL (1985) Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 24:5480–5486PubMedCrossRef

Fang S, Repo H, Joensuu H, Orpana A, Salven P (2011) High serum angiogenin at diagnosis predicts for failure on long-term treatment response and for poor overall survival in non-Hodgkin lymphoma. Eur J Cancer 47:1708–1716PubMedCrossRef

Folkman J, Klagsbrun M (1987) Angiogenic factors. Science 235:442–447PubMedCrossRef

Hartmann A, Kunz M, Köstlin S, Gillitzer R, Toksoy A, Bröcker EB, Klein CE (1999) Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res 59:1578–1583PubMed

Houge G, Døskeland SO (1996) Divergence towards a dead end? Cleavage of the divergent domains of ribosomal RNA in apoptosis. Experientia 52:963–967PubMedCrossRef

10.

Hu G, Riordan JF, Vallee BL (1994) Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. Proc Natl Acad Sci USA 91:12096–12100PubMedCrossRef

11.

Hu GF, Riordan JF (1993) Angiogenin enhances actin acceleration of plasminogen activation. Biochem Biophys Res Commun 197:682–687PubMedCrossRef

12.

Krejsgaard T, Vetter-Kauczok CS, Woetmann A, Lovato P, Labuda T, Eriksen KW, Zhang Q, Becker JC, Ødum N (2006) Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 20:1759–1766PubMedCrossRef

13.

Lyons RM, Gentry LE, Purchio AF, Moses HL (1990) Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 110:1361–1367PubMedCrossRef

14.

Mazur G, Woźniak Z, Wróbel T, Maj J, Kuliczkowski K (2004) Increased angiogenesis in cutaneous T-cell lymphomas. Pathol Oncol Res 10:34–36PubMedCrossRef

15.

Moenner M, Gusse M, Hatzi E, Badet J (1994) The widespread expression of angiogenin in different human cells suggests a biological function not only related to angiogenesis. Eur J Biochem 226:483–490PubMedCrossRef

16.

Musolino C, Alonci A, Bellomo G, Loteta B, Quartarone E, Gangemi D, Massara E, Calabrò L (2004) Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications. Eur J Haematol 72:416–419PubMedCrossRef

17.

Rendl M, Mayer C, Weninger W, Tschachler E (2001) Topically applied lactic acid increases spontaneous secretion of vascular endothelial growth factor by human reconstructed epidermis. Br J Dermatol 145:3–9PubMedCrossRef

18.

Rybak SM, Fett JW, Yao QZ, Vallee BL (1987) Angiogenin mRNA in human tumor and normal cells. Biochem Biophys Res Commun 146:1240–1248PubMedCrossRef

19.

Sugaya M, Fang L, Cardones AR, Kakinuma T, Jaber SH, Blauvelt A, Hwang ST (2006) Oncostatin M enhances CCL21 expression by microvascular endothelial cells and increases the efficiency of dendritic cell trafficking to lymph nodes. J Immunol 177:7665–7672PubMed

20.

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of tumors of haematopoietic and lymphoid tissues, 4th edn. IARC Press, Lyon

21.

Tello-Montoliu A, Patel JV, Lip GY (2006) Angiogenin: a review of the pathophysiology and potential clinical applications. J Thromb Haemost 4:1864–1874PubMedCrossRef

22.

Tschesche H, Kopp C, Hörl WH, Hempelmann U (1994) Inhibition of degranulation of polymorphonuclear leukocytes by angiogenin and its tryptic fragment. J Biol Chem 269:30274–30280PubMed

23.

Vacca A, Moretti S, Ribatti D, Pellegrino A, Pimpinelli N, Bianchi B, Bonifazi E, Ria R, Serio G, Dammacco F (1997) Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. Eur J Cancer 33:1685–1692PubMedCrossRef

24.

Verstovsek S, Kantarjian H, Aguayo A, Manshouri T, Freireich E, Keating M, Estey E, Albitar M (2001) Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome. Br J Haematol 114:290–295PubMedCrossRef

25.

Vihinen P, Kallioinen M, Vuoristo MS, Ivaska J, Syrjänen KJ, Hahka-Kemppinen M, Kellokumpu-Lehtinen PL, Pyrhönen SO (2007) Serum angiogenin levels predict treatment response in patients with stage IV melanoma. Clin Exp Metastasis 24:567–574PubMedCrossRef

Title: Angiogenin levels are increased in lesional skin and sera in patients with erythrodermic cutaneous T cell lymphoma
Authors: Tomomitsu Miyagaki
Makoto Sugaya
Hiraku Suga
Kaname Akamata
Hanako Ohmatsu
Hideki Fujita
Yoshihide Asano
Yayoi Tada
Takafumi Kadono
Shinichi Sato
Publication date: 01-07-2012
Publisher: Springer-Verlag
Published in: Archives of Dermatological Research / Issue 5/2012
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-012-1238-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Angiogenin levels are increased in lesional skin and sera in patients with erythrodermic cutaneous T cell lymphoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2012

Role of COX-2 activity and CRP levels in patients with non-melanoma skin cancer. −765G>C PTGS2 polymorphism and NMSC risk

Association of TGFβ1 and clinical factors with scar outcome following melanoma excision

A decreased ratio between serum levels of the antagonistic angiopoietins 1 and 2 indicates tumour progression of malignant melanoma

No association of vitamin D metabolism-related polymorphisms and melanoma risk as well as melanoma prognosis: a case–control study

Ichthyin/NIPAL4 localizes to keratins and desmosomes in epidermis and Ichthyin mutations affect epidermal lipid metabolism

DNA damage after acute exposure of mice skin to physiological doses of UVB and UVA light